Germany's Stada Arzneimittel says it's checking out potential takeover targets, looking to continue its recent series of acquisitions, Forbes reports. The generics maker said it may have to raise new capital for the deals so it can maintain its equity ratios.
Stada has been expanding in eastern Europe through takeovers to combat a shrinking generics market at home in Germany. Among its buys: Hemofarm of Serbia, which it bought for $780 million, and Russia's Makiz. Still, the company isn't doing badly at home: Its domestic market lost 3 percent overall last year, but Stada managed to grow its own domestic sales by 20 percent. On the whole, its sales rose by 26 percent to $2.48 billion.
- check out the Forbes coverage
Stada sells off U.S. sub, exits market. Report
Stada buys Russian pharma group. Report